Mitochondria and Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

December 31, 2018

Conditions
Hemodialysis-Induced SymptomMitochondrial Diseases
Interventions
DRUG

Icatibant

Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.

DRUG

Placebo

Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT03177798 - Mitochondria and Chronic Kidney Disease | Biotech Hunter | Biotech Hunter